Immunophenotyping of melanomas for tyrosinase: implications for vaccine development
about
Endoplasmic reticulum retention is a common defect associated with tyrosinase-negative albinismPDZ domain protein GIPC interacts with the cytoplasmic tail of melanosomal membrane protein gp75 (tyrosinase-related protein-1)Selective down-regulation of tyrosinase family gene TYRP1 by inhibition of the activity of melanocyte transcription factor, MITFA testicular antigen aberrantly expressed in human cancers detected by autologous antibody screeningElevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic statusThe class I antigen-processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosolProper folding and endoplasmic reticulum to golgi transport of tyrosinase are induced by its substrates, DOPA and tyrosine.Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanomaHeterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma.Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide.Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer.T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance.T-cell-directed cancer vaccines: the melanoma model.Immunohistochemical markers of melanocytic tumors.Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization.Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma modelAberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cellsEvaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanomaMelanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas.DNA vaccination: using the patient's immune system to overcome cancerProtein Expression Analysis of Melanocyte Differentiation Antigen TRP-2.Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.N-linked carbohydrates in tyrosinase are required for its recognition by human MHC class II-restricted CD4(+) T cells.High homogeneity of MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: implications for protocol design of therapeutic antigen-specific vaccination strategies.
P2860
Q22254144-1E61065F-2124-44C9-870B-63DE7F7A003CQ24291415-B452D5A4-211E-4C07-B133-B35350B8769BQ24540321-E844E050-5FAD-4A51-A324-FC221A26DAAAQ24564781-FD4E491F-6B01-417D-BC79-3BE1CF84A56CQ24803279-E29E45E4-505E-49D5-BBE3-FE8EC7530CBBQ30442820-DF559D2E-4F7F-4D8C-8D95-A4239E30419AQ31735253-CF9885B2-2E73-4BE9-A9CD-3223760535B0Q33606137-6282F271-1B6A-4D0C-AAD3-12E143942ADBQ33827463-8D644FE4-D821-4C70-A4E5-32D51AE4E0AAQ33909760-E30325F6-4518-458C-ACF0-0ACB13A95DDCQ34353878-B575A066-DA2F-46F8-8DE8-D8DE70F5F5A9Q34452013-78ACF9DB-4500-42EC-97C9-14B2E3E74FB1Q34452071-AD1D6E10-8576-4C70-AAAF-9BAE480AB3F7Q35071130-E2C5A5E2-F933-40D3-851E-97DC4A25F6A3Q35948302-71DEA57C-9592-4C7E-BEDD-CA587422EC10Q36131100-DC888B61-E5F5-4202-9B52-34800DD1E2A1Q36181464-5E2441E8-97C9-45B6-AEE1-0355AEFB1080Q36294815-3AF6C2DA-DF91-4911-8DB8-B1E6EEBB1BA3Q36366680-A97C4374-25CC-429E-8A30-F9ADC7E16665Q36400634-9282C4F3-DD91-46DE-905E-B7D4F391AECDQ37562613-4FB732E6-3E38-49AA-BB06-E9C4030F4ED8Q37825422-10AB80B9-9C74-4202-AC91-CE797DAB01DDQ38382073-1F8F46D1-9A69-4E7E-8DE4-D77DCE21100EQ38465242-34D67B67-14F9-4ABC-BE07-0098FD5F0440Q38471940-4C69D3D8-FB89-4131-A102-049A8E992768Q40782194-3E3C59FE-2D82-48F5-A3B1-25A52CEFA8E2Q45888192-00FA84A5-F019-4091-B29C-EB567A449ED5
P2860
Immunophenotyping of melanomas for tyrosinase: implications for vaccine development
description
1995 nî lūn-bûn
@nan
1995 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Immunophenotyping of melanomas for tyrosinase: implications for vaccine development
@ast
Immunophenotyping of melanomas for tyrosinase: implications for vaccine development
@en
type
label
Immunophenotyping of melanomas for tyrosinase: implications for vaccine development
@ast
Immunophenotyping of melanomas for tyrosinase: implications for vaccine development
@en
prefLabel
Immunophenotyping of melanomas for tyrosinase: implications for vaccine development
@ast
Immunophenotyping of melanomas for tyrosinase: implications for vaccine development
@en
P2093
P2860
P356
P1476
Immunophenotyping of melanomas for tyrosinase: implications for vaccine development
@en
P2093
P2860
P304
P356
10.1073/PNAS.92.18.8125
P407
P577
1995-08-01T00:00:00Z